Aminoquinoline-based Re(I) tricarbonyl complexes : Insights into their antiproliferative activity and mechanisms of action
(2024) In European Journal of Medicinal Chemistry 266.- Abstract
In an effort to develop new potent anticancer agents, two Schiff base rhenium(I) tricarbonyl complexes, containing the ubiquitous aminoquinoline scaffold, were synthesized. Both aminoquinoline ligands and Re(I) complexes showed adequate stability over a 48-h incubation period. Furthermore, the cytotoxic activity of the precursor ligands and rhenium(I) complexes were evaluated against the hormone-dependent MCF-7 and hormone-independent triple negative MDA-MB-231 breast cancer cell lines. Inclusion of the [Re(CO)3Cl]+ entity significantly enhanced the cytotoxicity of the aminoquinoline Schiff base ligands against the tested cancer cell lines. Remarkably, the incorporation of the Schiff-base iminoquinolyl entity... (More)
In an effort to develop new potent anticancer agents, two Schiff base rhenium(I) tricarbonyl complexes, containing the ubiquitous aminoquinoline scaffold, were synthesized. Both aminoquinoline ligands and Re(I) complexes showed adequate stability over a 48-h incubation period. Furthermore, the cytotoxic activity of the precursor ligands and rhenium(I) complexes were evaluated against the hormone-dependent MCF-7 and hormone-independent triple negative MDA-MB-231 breast cancer cell lines. Inclusion of the [Re(CO)3Cl]+ entity significantly enhanced the cytotoxicity of the aminoquinoline Schiff base ligands against the tested cancer cell lines. Remarkably, the incorporation of the Schiff-base iminoquinolyl entity notably enhanced the cytotoxic activity of the Re(I) complexes, in comparison with the iminopyridyl entity. Notably, the quinolyl-substituted complex showed up to three-fold higher activity than cisplatin against breast cancer cell lines, underpinning the significance of the quinoline pharmacophore in rational drug design. In addition, the most active Re(I) complex showed better selectivity towards the breast cancer cells over non-tumorigenic FG-0 cells. Western blotting revealed that the complexes increased levels of γH2AX, a key DNA damage response protein. Moreover, apoptosis was confirmed in both cell lines due to the detection of cleaved PARP. The complexes show favourable binding affinities towards both calf thymus DNA (CT-DNA), and bovine serum albumin (BSA), and the order of their interactions align with their cytotoxic effects. The in silico molecular simulations of the complexes were also performed with CT-DNA and BSA targets.
(Less)
- author
- Zinman, Paige S. ; Welsh, Athi ; Omondi, Reinner O. ; Khan, Saif ; Prince, Sharon ; Nordlander, Ebbe LU and Smith, Gregory S.
- organization
- publishing date
- 2024-02-15
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Aminoquinoline, Cytotoxicity, DNA/BSA binding, Molecular docking, Rhenium(I)
- in
- European Journal of Medicinal Chemistry
- volume
- 266
- article number
- 116094
- publisher
- Elsevier Masson SAS
- external identifiers
-
- pmid:38219660
- scopus:85182567539
- ISSN
- 0223-5234
- DOI
- 10.1016/j.ejmech.2023.116094
- language
- English
- LU publication?
- yes
- id
- e6fbc77e-666b-4d44-9973-206f0310e373
- date added to LUP
- 2024-02-19 14:51:32
- date last changed
- 2024-04-19 16:52:49
@article{e6fbc77e-666b-4d44-9973-206f0310e373,
abstract = {{<p>In an effort to develop new potent anticancer agents, two Schiff base rhenium(I) tricarbonyl complexes, containing the ubiquitous aminoquinoline scaffold, were synthesized. Both aminoquinoline ligands and Re(I) complexes showed adequate stability over a 48-h incubation period. Furthermore, the cytotoxic activity of the precursor ligands and rhenium(I) complexes were evaluated against the hormone-dependent MCF-7 and hormone-independent triple negative MDA-MB-231 breast cancer cell lines. Inclusion of the [Re(CO)<sub>3</sub>Cl]<sup>+</sup> entity significantly enhanced the cytotoxicity of the aminoquinoline Schiff base ligands against the tested cancer cell lines. Remarkably, the incorporation of the Schiff-base iminoquinolyl entity notably enhanced the cytotoxic activity of the Re(I) complexes, in comparison with the iminopyridyl entity. Notably, the quinolyl-substituted complex showed up to three-fold higher activity than cisplatin against breast cancer cell lines, underpinning the significance of the quinoline pharmacophore in rational drug design. In addition, the most active Re(I) complex showed better selectivity towards the breast cancer cells over non-tumorigenic FG-0 cells. Western blotting revealed that the complexes increased levels of γH2AX, a key DNA damage response protein. Moreover, apoptosis was confirmed in both cell lines due to the detection of cleaved PARP. The complexes show favourable binding affinities towards both calf thymus DNA (CT-DNA), and bovine serum albumin (BSA), and the order of their interactions align with their cytotoxic effects. The in silico molecular simulations of the complexes were also performed with CT-DNA and BSA targets.</p>}},
author = {{Zinman, Paige S. and Welsh, Athi and Omondi, Reinner O. and Khan, Saif and Prince, Sharon and Nordlander, Ebbe and Smith, Gregory S.}},
issn = {{0223-5234}},
keywords = {{Aminoquinoline; Cytotoxicity; DNA/BSA binding; Molecular docking; Rhenium(I)}},
language = {{eng}},
month = {{02}},
publisher = {{Elsevier Masson SAS}},
series = {{European Journal of Medicinal Chemistry}},
title = {{Aminoquinoline-based Re(I) tricarbonyl complexes : Insights into their antiproliferative activity and mechanisms of action}},
url = {{http://dx.doi.org/10.1016/j.ejmech.2023.116094}},
doi = {{10.1016/j.ejmech.2023.116094}},
volume = {{266}},
year = {{2024}},
}